ExpressCells United States

ExpressCells is genetic-engineering company that creates custom and catalog knock-in cell lines for biological research. Our approach uses CRISPR plus our patent-pending plasmid system that creates cell lines up to 75% faster than older technologies and allows multiple knock-ins. Our living cells replicate diseases or have proteins glow in multiple colors, speeding drug development. We are generating revenue through e-commerce, online promotion, and sales representatives.

Website:
xpresscells.com
Company Size (Fulltime employees)
Year of foundation
2018
Please specify your partnering goal
Identify companies that can commercialize our cell lines in China and other Asian markets
Headquartner in China
Assets Information 1
Customer Knock-In Cell Lines
Assets Information 2
Catalog Cell Lines
Assets Information 3
Knock-in Stem Cells
Biotech/Pharma Asset Stage
Your Research Tool and Service name
Knock-in Cell Lines
Service Description
We create custom knock-in cell lines in as few as 30 days. Using our patent-pending FAST-HDR plasmid system, we can knock 1-3 genes into precise locations in cell lines. These knock-ins can be reporters, overexpression models, or have point mutations inserted.
Target client type
Research scientists in pharmaceuticals and biotech who conduct experiments on cell lines
Slides Deck
(pdf, 1.48MB)
Mr. Matt Handel
LinkedIn logo CEO 
Functionality

Eyedetec Medical, Inc. United States

Dry Eye Disease (DED) significantly impacts quality of life and vision, and the incidence is growing 7% annually (30M in US, 350M worldwide). Time spent on digital screens is accelerating this increase. There is currently no cure, and available treatments often create fear, anxiety, and discomfort, and are costly. Eyedetec Medical is developing a novel, internet connected, non-invasive platform medical device for treating patients that is effective, soothing, and relaxing, and will be used by patients in office and at home. The scalability and flexibility of this approach enables doctors to meet growing patient demand while generating meaningful new revenue. Proof-of-concept clinical data is positive. This novel therapy is easier to use, much more comfortable for the patient, and significantly less expensive than alternatives.

Website:
www.eyedetec.com
Company Size (Fulltime employees)
Year of foundation
2006
Please specify your partnering goal
Company that will invest, with a sales team, and potential to acquire.
Headquartner in China
Medtech Information 1
Eye Lipid Mobilizer|Hands-free, externally delivered, novel treatment for dry eye disease.|USA
Medtech Development Stage
Dr. Barry Linder, MD, MS
Dr. Barry Linder, MD, MS
LinkedIn logo President & CEO 
Functionality